Abstracts tagged "Antibodies and myositis"

Abstract Number: 299 • 2015 ACR/ARHP Annual Meeting
Subcutaneous Edema, Distal Weakness and Dysphagia Associated with the NXP2 Antibody
Jemima Albayda¹, Iago Pinal-Fernandez², Lisa Christopher-Stine³, Sonye K. Danoff⁴, Cheilonda Johnson⁵, Christopher Mecoli⁶, Julie J. Paik⁷, Alim Ramji⁸ and Andrew Mammen⁹, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Medicine/Pulmonology, Johns Hopkins University, Baltimore, MD, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸School of Medicine, Johns Hopkins University, Baltimore, MD, ⁹Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Myositis specific antibodies are known to be associated with specific phenotypes. The unusual presentation of subcutaneous edema, distal weakness and dysphagia was seen in…
Abstract Number: 1945 • 2012 ACR/ARHP Annual Meeting
Anti-Transcription Intermediary Factor 1-Gamma (TIF1-Υ) Autoantibody Detection by ELISA and Immunoprecipitation in a Prospective Myositis Cohort: Predictive Value for Cancer Associated Myositis
Rohit Aggarwal¹, Noreen Fertig², Danielle Goudeau³, Chad Stephans⁴, Qi Zengbiao⁵, Diane Koontz⁵, Mary Lucas⁶, Marc C. Levesque³ and Chester V. Oddis⁷, ¹Rheumtology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis [particularly dermatomyositis (DM)] is associated with cancer and anti-transcription intermediary factor-1 gamma (TIF1γ) is a serologic risk factor for cancer associated myositis (CAM).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].